Stocks Icon


Aphria Inc. is International

Our strong international presence means future growth as international markets evolve.


Aphria One

Leamington, ON Canada

Our 87-acre campus is home to our corporate headquarters and 1,100,000 square feet of premier greenhouse production. Aphria One is GMP certified to the USFDA standard and has a total annual production capacity of 110,000 kg.

Aphria Diamond

Leamington, ON Canada

Aphria Inc.’s 51% owned subsidiary, Aphria Diamond, is situated on a 100-acre campus featuring 1,300,000 square feet that will be capable of producing 140,000 kg annually. Aphria Diamond has applied for a second site cultivation license pursuant to the Cannabis Act and, pending approval from Health Canada, expects to begin production in 2019.

Broken Coast Cannabis

Duncan, British Columbia, Canada

Aphria Inc.’s West Coast subsidiary, Broken Coast, is an award-winning craft grower that delivers a premium product synonymous with the legacy of B.C.-bud. Broken Coast’s craft-grown cannabis is cultivated on the shores of the Salish Sea in small batches, using single-strain growing rooms. With an annualized production capability of 5,000 kg, Broken Coast continues to develop new strains that represent the highest level of premium cannabis.


ARA Avanti Rx

Brampton, Ontario, Canada

Aphria Inc.’s wholly-owned subsidiary, Avanti Rx, is a Health Canada-approved GMP-certified lab focusing on analytical testing, product development, extraction, purification, and formulation.


Colcanna SAS

Chinchiná, Caldas, Colombia

Aphria Inc.’s 90% owned subsidiary, Colcanna is located in the Coffee Zone of Colombia with licenses for the cultivation, processing, export and research of psychoactive and non-psychoactive cannabis. Situated on 54 acres of land, Colcanna is currently building cultivation capacity suitable for supplying the country and the region with high-quality medical cannabis. Greenhouses are planned for more than 20 acres of the property and are expected to achieve an initial annualized production of 30,000 kg.



Buenos Aires, Argentina

Founded in 2007, Aphria Inc.’s wholly-owned subsidiary, ABP, is an established pharmaceutical import and distribution company that was granted the first Argentina Ministry of Health permit for the import of pharmaceutical-grade medical cannabis. ABP distributes to an extensive network of pharmacies, distributors, government clinics and hospitals throughout Argentina. ABP is focused on the research and clinical study of medical cannabis, including its partnership with Hospital de Pediatria Garrahan, a leading pediatric hospital in Buenos Aires. Aphria and ABP, in close partnership with the Argentinean government, continue to advance opportunities for medical cannabis in the country, including the potential for in-country cultivation.


Marigold Projects Jamaica Limited

Kingston, Jamaica

Marigold Projects, a 49% owned subsidiary of Aphria Inc., is a cannabis company that holds a Tier 3 license to cultivate more than five acres of land with cannabis for medical, scientific and therapeutic purposes. Marigold Projects cultivation farm is fully operational, and by December 2018 had harvested approximately 2,500kg of cannabis. The company maintains an additional 10 acres of vacant land in anticipation of expanding its cultivation operations. Marigold Projects expects to open its first herb houses in 2019, under the name Sensi Medical Cannabis House, located in Kingston and Portmore. Additional herb house locations are planned for other high-demand regions of Jamaica.

Aphria Germany

Densborn, Germany

Aphria Inc.’s subsidiary, Aphria Germany, was granted a cultivation license for four of the nine lots awarded by the German Federal Institute for Drugs and Medical Devices in April 2019. Construction is underway on an R&D indoor growing facility in Neumünster and a state-of-the-art GMP certified cannabis vault in Bad Bramstedt for the import of cannabis flowers and oil from Canada and Denmark. Aphria Germany also holds a 25.1% interest in Berlin-based Schöneberg Hospital, which provides access to both doctors and patients for education on the benefits of medical cannabinoids. In April 2019, the company launched CannRelief, a CBD-based nutraceutical and cosmetics product line for the German market, produced in the EU and distributed by CC Pharma, a subsidiary of Aphria Inc. with access to more than 13,000 pharmacies throughout Germany.


CC Pharma

Densborn, Germany

Aphria Inc.’s subsidiary CC Pharma is a leading importer and distributor of EU-pharmaceuticals, including medical cannabis, to more than 13,000 pharmacies in Germany and the rest of Europe. Through CC Pharma, Aphria is creating a platform that brings together demand, supply, and distribution within the EU.


ASG Pharma Ltd.

Valleta, Malta

Aphria Inc.’s Malta-based subsidiary ASG Pharma is a high-capacity EU GMP-certified lab that is well-poised to become a cornerstone for testing and research and development of medical cannabis in Europe. ASG received the first import certificate for medical cannabis issued by the Malta Ministry of Health for R&D purposes. Following the completion of the upgrade of its processing and manufacturing capabilities, ASG will serve as Aphria’s hub for importing, processing, packaging and distribution of EU-GMP certified cannabis products in Europe.


Vado Ligure, Italy

Possessing one of only seven cannabis-based and cannabinoids import licenses in Italy for delivery to pharmacies, Aphria Inc.’s Italian subsidiary, the FL-Group, is fully authorized for the distribution of pharmaceutical products. The FL-Group acts as Aphria’s distributor to the Italian cannabis market.

Strategic Partnership with Schroll Medical

Arslev, Denmark

Aphria Inc. has entered into a Strategic Partnership with Schroll Medical, a subsidiary of prominent European flower producer Schroll Flowers. The Partnership will pursue the cultivation and worldwide distribution of organic, EU GMP-certified medical cannabis. Schroll Medical has already received its license for the cultivation of medical cannabis from the Danish Medicines Agency, and currently owns property where cultivation has already begun.

CannInvest Africa Ltd.

Maseru, Lesotho

A Strategic Partnership with Verve Group of Companies, CannInvest, a South African corporation with 50% Aphria Inc. ownership, holds a 60% ownership interest in Verve Dynamics Incorporated, a licensed producer of medical cannabis extracts located in the Kingdom of Lesotho. CannInvest is also expanding its footprint in Africa through additional licensing and commercial opportunities across the continent.


Melbourne, Australia

A licensed producer of medical cannabis, Althea is listed on the Australia Securities Exchange and is 25% owned by Aphria Inc. Founded in 2017, Althea maintains a license to import, cultivate, and manufacture medical cannabis in Australia. While Althea builds out its greenhouse campus in the Mornington Peninsula, the Australian company is importing and supplying five Aphria co-branded medicinal products to eligible patients through a supply agreement with Aphria.


Tetra Bio-Pharma

Ottawa, ON, Canada

Aphria Inc. is supplying Tetra BioPharma with dried flower and cannabis oil products with which they are performing clinical trials.



Sydney, Australia

Aphria Inc. is producing and supplying high-yield cannabis extracts for Medlab to be used in a human trial of their NanoCelle mucosal spray to test the management of intractable pain in oncology patients – the first trial of its kind globally.



Sydney, Australia

Aphria Inc. is supplying cannabis oil to CannPal for use in clinical studies related to animal health, including chronic pain in cats and dogs.


Hospital Pediatria de Garrahan

Buenos Aires, Argentina

Through its Argentina-based subsidiary, ABP, S.A., Aphria Inc.’s is supplying its renowned Rideau CBD oil to Hospital de Pediatria Garrahan, a leading pediatric hospital located in Buenos Aires, for use in a clinical study focused on treating refractory epilepsy in children.


Rapid Dose Therapeutics

Burlington, ON, Canada

RDT’s innovative QuickStrip™ is an easy-to-use, safe and effective oral fast-dissolving drug delivery system, developed in conjunction with McMaster University through the renowned Adronov Research Group, providing accurate dosing and potency. Aphria Inc. holds the exclusive global preferred rights to license, manufacture, distribute and sell RDT’s QuickStrip™ innovative, proprietary delivery technology for both medical and adult-use cannabis markets.


Manna Molecular Science

Worcester, MA, USA

The Manna cannabis transdermal patch has been developed by pharmaceutical scientists from Massachusetts Institute of Technology using state-of-the-art product design and research methods. It works for all cannabinoids and is designed to work with high-quality, whole-plant cannabis extracts, which are printed on each patch with pharmaceutical quality. Each patch is latex- and allergen-free and delivers the dose automatically through the skin over the course of 12 hours. Aphria Inc. holds a worldwide license agreement to produce and sell the patches containing cannabis oils for its established suite of medical and adult-use brands.



Toronto, Ontario, Canada

Powered by Aphria Inc.’s best-in-class cannabis production and Perennial’s industry-leading expertise in strategic brand development, this partnership focuses on creating highly differentiated, market-disrupting brands and products that deliver adult-use consumers a unique and targeted cannabis experience